AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01963325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus Abraxane
Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
Study NCT04668196 — intervention group
Intervention type: DEVICE
Intervention: High-flow nasal cannula treatment
Description: Standard operating procedures represented by hihg-flow nasal cannula oxygen therapy
Study NCT04668196 — intervention group
Intervention type: DEVICE
Intervention: Continuous positive airway pressure (CPAP) treatment
Description: Standard operating procedures represented by continuous positive airway pressure (CPAP) therapy
Study NCT04668196 — intervention group
Intervention type: DEVICE
Intervention: Noninvasive ventilation treatment
Description: Standard operating procedures represented by noninvasive ventilation treatment
Study NCT03918746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet Attachment-Based Compassion Therapy (iABCT)
Description: The internet version of Attachment-Based Compassion Therapy (iABCT) will be developed to be totally self-applied over the Internet through the website www.psicologiaytecnologia.com designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and University of Valencia). The iABCT will consist of eight sequential modules: Module 0) Welcome module: approaching to the compassion; Module 1) Preparing ourselves for compassion. Kind attention; Module 2) Discovering our compassionate world; Module 3) Developing our compassionate world; Module 4) Understanding our relationship with compassion; Module 5) Working on ourselves; Module 6) Understanding the importance of forgiveness; Module 7) Consolidating the practice of compassion~The content will present through texts, audios, videos, pictures, vignettes, and interactive exercises. Downloadable PDF files will be available so that users can review them offline.
Study NCT00466882 — intervention group
Intervention type: DEVICE
Intervention: Inamed Lap-Band System
Description: Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
Study NCT01405625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictogram-based asthma action plan
Description: Asthma action plan using plain language, pictograms, and photographs
Study NCT01405625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AAAAI standard of care written action plan
Study NCT00572195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNS® System
Description: The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
Study NCT02716389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Zebris CMS 70
Study NCT02716389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3-D Bulls Eye Spirit Meter
Study NCT01489943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 500 mg
Description: Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
Study NCT01489943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg
Description: Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
Study NCT01489943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg
Description: Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
Study NCT01489943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Description: Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
Study NCT01489943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Description: Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
Study NCT02026323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture
Study NCT03424434 — intervention group
Intervention type: OTHER
Intervention: Survey diffusion
Description: The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
Study NCT03977558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Isocaloric diet including \~50g canola oil
Study NCT03977558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: ESC/EAS Guidelines for the management of dyslipidemias
Study NCT03089437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Standing
Description: Subject will stand for 12 hours and undergo a high fat tolerance test the subsequent day
Study NCT03089437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Sitting
Description: Subject will sit for 12 hours and undergo a high fat tolerance test the subsequent day
Study NCT02357251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced recovery protocol
Study NCT03846648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cypep-1
Description: Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest.
Study NCT03846648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cypep-1
Description: Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest.
Study NCT03289234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg of edaravone will be administered intravenously over 60 minutes
Study NCT00939445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online HDF
Description: Online HDF
Study NCT00939445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Daily Hemodialysis
Description: Short Daily Hemodialysis
Study NCT02669264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-402
Description: Intravenous infusion
Study NCT02521675 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual algorithm
Description: The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible
Study NCT02521675 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabrasport algorithm
Description: The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week test algorithms usual and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90min after lunch These activities shall not exceed one hour
Study NCT02521675 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Rest
Description: The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.~The patient goes home and he will not perform any physical activity during the week
Study NCT02521675 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Holter Glycemic Ipro2, Medtronic
Study NCT01562795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonsteroid anti-inflammatory drops
Description: nonsteroid anti-inflammatory drops plus artificial tear substitute
Study NCT01562795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: corticosteroids plus artificial tear substitute
Study NCT01562795 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: artificial tear substitute
Description: artificial tear substitute alone
Study NCT00969332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: 0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday
Study NCT02226796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
Study NCT00818714 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD
Study NCT00654485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00654485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT00815867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta (NeoRecormon ®)
Description: comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections
Study NCT02651766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cupping massage
Description: Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
Study NCT03570398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: unenhanced abdomino-pelvic CT scan
Description: unenhanced abdomino-pelvic CT scan
Study NCT03570398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: abdominal ultrasound
Description: abdominal ultrasound
Study NCT05100290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperventilation Provocation Test (HPTest)
Description: During the HPTest, the subject is comfortably seated in a chair with armrests and breathes in a mouthpiece with a salivary collector and a nasal clamp. Parameters of ventilation and gas exchange are analyzed via an Oxycon ProTM (SN808008) with TripleV-Volume Sensor digital(Jaeger).~The HPTest begins with a 3-minutes adaptation phase during which the patient is asked to breathe normally. During the 3-minutes of voluntary hyperventilation phase, the patient is asked to increase his tidal volume and support a breath rate of at least 30/min in order to reduce his PETCO2 by at least 50%. During the recovery phase of the HPTest, the patient is invited to regain a natural breathing for 5 minutes, without guidance on tidal volume or breath rate.
Study NCT01135329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV daily on Day +3 and Day +4.
Study NCT01135329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg PO three times daily (max daily dose of 3g) starting on Day +5.
Study NCT01135329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Dosed based on drug levels; begin on Day +5 at 1 mg IV daily.
Study NCT02270047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange nectar
Description: Orange nectar
Study NCT02270047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange Nectar with fibre
Study NCT04411394 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Body Perception Questionnaire and Hospitalized Anxiety and Depression Scale
Study NCT02464813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
Study NCT02464813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
Study NCT02464813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
Study NCT02464813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
Study NCT05542043 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures.
Study NCT00774514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
Study NCT02405910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT01718678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: it is kind of drug
Study NCT01718678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is Placebo
Study NCT03284814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Standard product (SP)
Description: hard capsules, 100 mg
Study NCT03284814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Standard product (SP)
Description: hard capsules, 100 mg
Study NCT03284814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Comparative product (CP)
Description: soft-gel capsules, 100 mg
Study NCT03284814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Comparative product (CP)
Description: soft-gel capsules, 100 mg
Study NCT03284814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Investigational product (IP)
Description: syrup, 100 mg
Study NCT03284814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple dose intervention with Standard product (SP)
Description: hard capsules, 100 mg - 14 days
Study NCT03284814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple dose intervention with Comparative product (CP)
Description: soft-gel capsules, 100 mg - 14 days
Study NCT03284814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple dose intervention with Investigational product (IP)
Description: syrup, 100 mg - 14 days
Study NCT03269630 — intervention group
Intervention type: OTHER
Intervention: No intervention. Biospecimen collection only
Description: Biospecimen collection
Study NCT02962453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning walk
Description: gait training with Morning walk three times during 5 minutes with 5 minute break a day over 5 weekdays
Study NCT02962453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ground Walker
Description: gait training with ground walker until corresponding 200 steps during 5 minutes with 5 minute break a day over 5 weekdays
Study NCT00322231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zoster vaccine live (ZOSTAVAX™)
Description: 1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
Study NCT00322231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: 1 dose 0.65 mL/dose subcutaneous injection of placebo.
Study NCT02423330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strattice-LIFT
Description: Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
Study NCT02405910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT04854720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji® II LC CAPSULE
Description: Fuji® II LC is a resin modified glass ionomer contained, fluoride releasing and light-cured material. Since the product is tolerant to moisture and saliva, it's used for fissure sealant of newly erupted teeth.~Test 1 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.The tooth surface was rinsed with water and dried. Thereafter, Fuji® II LC was applied to the pits and fissures on the tooth surface using a brush. Then, the varnish was applied and cured according to the manufacturer's instructions.
Study NCT04854720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinpro™ XT Varnish
Description: Clinpro™ XT Varnish is a resin modified glass ionomer containing, fluoride-releasing, light-cured varnish. Since the product is tolerant to moisture and saliva, it is used for fissure sealant of newly erupted teeth. The product can be recharged with fluoride using fluoride-containing products.~Test 2 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 35% phosphoric acid was applied to all surfaces of the tooth for 15 seconds.Then the tooth surface was rinsed with water and dried. Thereafter, Clinpro™ XT Varnish was applied in compliance with the manufacturers' instructions.
Study NCT04854720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beautifil Flow
Description: Beautiful Flow is a Giomer contained, fluoride releasing and light cured material. The product contains pre-reacted glass ionomer particles (PRG). It is a high water resistant material. It is used for fissure sealant.~Test 3 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 7% phosphoric acid was applied to all surfaces of the tooth for 10 seconds. Then the tooth surface was rinsed with water and dried. Afterwards, a two-stage self-etch adhesive system was applied. Thereafter, Beautiful Flow was applied in compliance with the manufacturers' instructions.